FactSet Survey: Haemonetics Average Rating is Buy

Summary

According to a survey by FactSet, analysts give Haemonetics an average rating of ‘Buy’, with an average price target of $93.Trading View

Impact Analysis

The event is classified at the company level as it directly involves Haemonetics and how analysts perceive its stock. Recent developments show varying ratings: while FactSet and many analysts maintain a ‘Buy’ ratingTrading View, MarketBeat Ratings reports a ‘Moderate Buy’, reflecting some cautionMarket Beat. R.W. Baird’s upgrade to ‘Strong Buy’ could signal increased confidence in Haemonetics’ prospectsMarket Beat. Wall Street Zen’s downgrade to ‘Hold’ in May and JMP Securities maintaining ‘Outperform’ with a target price of $100 indicate divergence in analyst opinionMarket Beat. First-order effects include potential positive investor sentiment leading to stock price appreciation, given the majority ‘Buy’ rating. Second-order effects could involve increased market interest and trading activity in Haemonetics. Investment opportunities include considering Haemonetics as a ‘Buy’ candidate based on the consensus rating, while noting potential risks associated with differing analyst views and maintaining awareness of market volatility.